Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

Radiopharm Theranostics Achieves Confirmed Durable PartialResponse in Ongoing Phase 1 Trial of RAD204 in Patients withAdvanced Solid Tumors Post-Immunotherapy

Friday, July 24, 2026 1 min read
Key Takeaway: Radiopharm Theranostics has reported a confirmed durable partial response in its ongoing Phase 1 trial of RAD204. This trial focuses on patients with advanced solid tumors who have undergone immunotherapy. The results indicate potential efficacy and a positive outlook for the treatment's future development.

Market Sentiment Analysis

POSITIVE FACTORS

  • Confirmed durable partial response in patients
  • Ongoing Phase 1 trial shows promise
  • Focus on advanced solid tumors post-immunotherapy

Full Press Release Details

• Announcements , Updates
• PDF
• July 24, 2026
Loading Viewer…

More Announcements & Updates

• Announcements
• November 22, 2023
• Announcements
• March 15, 2024
• Announcements
• August 27, 2024
• Updates
• January 10, 2025

Radiopharm Theranostics Achieves Confirmed Durable PartialResponse in Ongoing Phase 1 Trial of RAD204 in Patients withAdvanced Solid Tumors Post-Immunotherapy

Radiopharm Theranostics Announces Positive Phase 2b Trial Resultsof RAD 101 for Diagnosis of Brain Metastases

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

• Radiopharm Theranostics Announces Positive Phase 2b Trial Resultsof RAD 101 for Diagnosis of Brain Metastases
• RAD Presentation July 2026
• Zacks Small-Cap Research 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is RAD204 used for?

RAD204 is being tested for its efficacy in patients with advanced solid tumors post-immunotherapy.

What were the results of the Phase 1 trial?

The Phase 1 trial of RAD204 achieved a confirmed durable partial response in patients.

Who conducted the RAD204 trial?

The trial was conducted by Radiopharm Theranostics.

What type of tumors is RAD204 targeting?

RAD204 targets advanced solid tumors in patients who have previously undergone immunotherapy.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics RAD204 advanced solid tumors immunotherapy clinical trial
Last updated: Jul 24, 2026